Rational approaches to human cancer immunotherapy

被引:113
作者
Davis, ID [1 ]
Jefford, M [1 ]
Parente, P [1 ]
Cebon, J [1 ]
机构
[1] Ludwig Inst Canc Res, Austin & Repatriat Med Ctr, Heidelberg, Vic 3084, Australia
关键词
review; vaccines; dendritic cells; T cells; antigens; peptides;
D O I
10.1189/jlb.0502261
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Over most of the 20(th) century, immunotherapy for cancer was based on empiricism. Interesting phenomena were observed in the areas of cancer, infectious diseases, or transplantation. Inferences were made and extrapolated into new approaches for the treatment of cancer. If tumors regressed, the treatment approaches could be refined further. However, until the appropriate tools and reagents were available, investigators were unable to understand the biology underlying these observations. In the early 1990s, the first human tumor T cell antigens were defined and dendritic cells were discovered to play a. pivotal role in antigen presentation. The current era of cancer immunotherapy is one of translational research based on known biology and rationally designed interventions and has led to a rapid expansion of the field. The beginning of the 21(st) century brings the possibility of a new era of effective cancer immunotherapy, combining rational, immunological treatments with conventional therapies to improve the outcome for patients with cancer.
引用
收藏
页码:3 / 29
页数:27
相关论文
共 340 条
[91]   Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias [J].
Goerner, M ;
Gooley, T ;
Flowers, MED ;
Sullivan, KM ;
Kiem, HP ;
Sanders, JE ;
Martin, PJ ;
Storb, R .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (01) :47-56
[92]   DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES [J].
GOLD, P ;
FREEDMAN, SO .
JOURNAL OF EXPERIMENTAL MEDICINE, 1965, 121 (03) :439-+
[93]  
Goldfried MR, 1997, IN SESSION-PSYCHOTH, V3, P1
[94]   Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer [J].
Gomella, LG ;
Mastrangelo, MJ ;
McCue, PA ;
Maguire, HC ;
Mulholland, SG ;
Lattime, EC .
JOURNAL OF UROLOGY, 2001, 166 (04) :1291-1295
[95]   NITROGEN MUSTARD THERAPY - USE OF METHYL-BIS(BETA-CHLOROETHYL)AMINE HYDROCHLORIDE AND TRIS(BETA-CHLOROETHYL)AMINE HYDROCHLORIDE FOR HODGKINS DISEASE, LYMPHOSARCOMA, LEUKEMIA AND CERTAIN ALLIED AND MISCELLANEOUS DISORDERS [J].
GOODMAN, LS ;
WINTROBE, MM ;
DAMESHEK, W ;
GOODMAN, MJ ;
GILMAN, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1946, 132 (03) :126-132
[96]  
GREENBERG PD, 1991, ADV IMMUNOL, V49, P281
[97]  
GRESSER I, 1961, P SOC EXP BIOL MED, V108, P799
[98]   INCREASED SURVIVAL IN MICE INOCULATED WITH TUMOR CELLS AND TREATED WITH INTERFERON PREPARATIONS [J].
GRESSER, I ;
BOURALI, C ;
LEVY, JP ;
FONTAINE.D ;
THOMAS, MT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1969, 63 (01) :51-&
[99]  
Gross L, 1943, CANCER RES, V3, P326
[100]   Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease:: prophylactic infusion of EBV-specific cytotoxic T cells [J].
Gustafsson, Å ;
Levitsky, V ;
Zou, JZ ;
Frisan, T ;
Dalianis, T ;
Ljungman, P ;
Ringden, O ;
Winiarski, J ;
Ernberg, I ;
Masucci, MG .
BLOOD, 2000, 95 (03) :807-814